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ABSTRACT Live virus vaccines are commonly used
in poultry production, particularly in broilers. Mas-
sive application and generation of a protective local
mucosal and humoral immunity with no adverse ef-
fects is the main goal for this strategy. Live virus vac-
cines can be improved by adding adjuvants to boost
mucosal innate and adaptive responses. In a previ-
ous study we showed that diatomaceous earth (DE)
can be used as adjuvant in inactivated vaccines. The
aim of this study was to test DE as adjuvant in an
Ark-DPI live infectious bronchitis virus (IBV) vac-
cine after ocular or spray application. Titrating the
virus alone or after addition of DE showed that DE
had no detrimental effect on the vaccine virus. How-
ever, adding DE to the vaccine did not induce higher
IgG titers in the serum and IgA titers in tears. It
also did not affect the frequency of CD4+ T cells,
CD8+ T cells and monocytes/macrophages in the blood
and the spleen determined by flow cytometry. In ad-
dition, protection generated against IBV homologous
challenges, measured by viral load in tears, respiratory
signs and histopathology in tracheas, did not vary when
DE was present in the vaccine formulation. Finally, we
confirmed through our observations that Ark vaccines
administered by hatchery spray cabinet elicit weaker
immune responses and protection against an IBV ho-
mologous challenge compared to the same vaccine de-
livered via ocular route.
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INTRODUCTION
Infectious bronchitis virus (IBV) is a Gamma coro-
navirus and the causal agent of IB. This disease causes
significant economic losses in the poultry industry
worldwide. To date, vaccination is the most widely used
method to control IBV. Live, attenuated vaccines are
the most commonly used in commercial poultry, par-
ticularly in broiler chickens. These vaccines are usu-
ally applied massively, through drinking water or spray
and/or individually via the eye drop route. The main
objective of the strategy is the generation of a protec-
tive local mucosal and humoral immunity. Secondary
effects of live, attenuated IBV vaccination, such as mild
respiratory signs as well as reduced egg production and
eggshell quality in layers (Bwala et al., 2012), are a
common outcome of their use. Due to the dozens of
recognized serotypes and even more genotypes, IBV
vaccination is challenging. The constant surveillance of
field strains and the use of homologous vaccines is the
only strategy to avoid failed protection against heterol-
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ogous strains (Capua et al., 1999; Cavanagh, 2003; Cook
et al., 2012). Therefore, improving live virus vaccines by
adding components, such as adjuvants to boost mucosal
innate and adaptive responses, is worth investigating.
Adjuvants have been used for decades in vaccine for-
mulation. Oil-based emulsions and aluminium deriva-
tives are routinely used in poultry inactivated vaccines
to increase their immunogenicity and improve antigen
delivery (Spickler and Roth, 2003). However, the use
of adjuvants substantially increases the price of inac-
tivated vaccines (Meeusen et al., 2007). Experimen-
tal utilization of adjuvants in live, attenuated vaccines
for poultry has been previously investigated. Mucosal
immune responses and protection of chickens against
Newcastle disease virus (NDV) challenge after live at-
tenuated vaccination of NDV were improved by using
chitosan nanoparticles as adjuvant (Zhao et al., 2012).
In addition, better antibody responses and protection
against challenge in chickens was demonstrated when a
live IBV vaccine was mixed with various types of adju-
vants compared with a non-adjuvanted vaccine (Deville
et al., 2012). Kjaerup and co-workers tested mannose-
binding lectin ligands such as mannan, chitosan, and
fructo-oligosaccharide as adjuvants in live IBV vaccines
with mixed success (Kjaerup et al., 2014). In this study,
we investigated the use of diatomaceous earth (DE) as
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an inexpensive and readily available adjuvant to boost
local mucosal and adaptive immune responses gener-
ated by an IBV live, attenuated vaccine.
DE is a natural siliceous sediment of fossilized re-
mains of microalgae called diatoms (Dolatabadi and
de la Guardia, 2011). The surface of DE is covered
with numerous porous silica capsules, increasing its to-
tal surface and allowing its use as a drug-delivery car-
rier (Aw et al., 2013; Wang et al., 2013). In addition,
silica, the main component of DE, has been reported to
have higher colloid stability than aluminium hydroxide
and to act as an adjuvant (Lincopan et al., 2009). We
have previously demonstrated that DE possess adjuvant
capabilities comparable to aluminium hydroxide when
used to formulate NDV inactivated vaccines (Nazmi et
al., 2017).
In this study, we investigated the use of DE as an in-
expensive and readily available adjuvant to boost local
mucosal and adaptive immune responses generated by
an IBV live, attenuated vaccine.
MATERIALS AND METHODS
IBV Vaccine and Challenge Virus
A commercial live, attenuated IBV Ark Type
live virus MILDVAC R©-ARK vaccine (Merck, Omaha,
NE) was reconstituted in sterile phosphate-buffered
saline (PBS) following the manufacturer’s instruc-
tions. The vaccine was titrated in 10-day-old, em-
bryonated, specific-pathogen-free (SPF) eggs (Charles
River, Franklin, CT) according to routine procedures
(Villegas, 2008). For the challenge, we used a virulent
IBV Ark-DPI strain kindly provided by Dr. Haroldo
Toro, Auburn University, Auburn, AL (Gallardo et al.,
2011).
IBV Vaccine Viability After Mixed with DE
To test the effect of DE on IBV ArkDPI vaccine
virus viability, the vaccine was reconstituted in tryptose
phosphate broth (TPB) (Becton, Dickinson and Com-
pany, Sparks, MD). Half of the vaccine final volume was
mixed with 20 mg of DE (Earthworks Health, Norfolk,
NE) per ml. Viral titration was performed immediately
in 10-day-old, embryonated SPF eggs as described in
Villegas, 2008.
Chickens
Seventy-two chicks were hatched from SPF eggs and
housed in wired cages inside BSL2 rooms at the Teach-
ing and Res. Animal Care Services at the University
of California, Davis. Feed and water were provided ad
libitum. All procedures and animal care were approved
by the Institutional Animal Care and Use Committee
(IACUC) at the University of California, Davis (proto-
col #: 17863).
Table 1. Experimental design showing number of birds,
viral titer, and DE dose in each experimental group.
Number Titer per DE
Group of birds dose (EID50%) (mg/dose)
Spray DE+IBV 13 103.7 2
Spray IBV 13 103.7 -
Spray DE 9 - 2
Ocular DE+IBV 13 103.7 2
Ocular IBV 15 103.7 -
Ocular DE 9 - 2
DE: diatomaceous earth, IBV: infectious bronchitis virus,
EID50%: embryo infectious dose 50%.
Experimental Design
At 3 d of age, SPF chickens were divided into 6
groups (Table 1). The first 3 groups were vaccinated
with DE+IBV, IBV alone or DE alone, using a stan-
dard hatchery spray cabinet (MSD, Gainesville, GA).
The other 3 groups were vaccinated intraocularly with
DE+IBV, IBV alone, or DE alone. The final vaccine
titer was 103.7-embryo infectious dose 50% (EID50%) per
dose per bird, regardless of the route of delivery, and
was chosen as a lower dose that would not elicit an op-
timal response without an adjuvant. The amount of DE
in each dose was 2 mg.
Twenty-one days post-vaccination (dpv), at 24 d of
age, birds from all groups were challenged with a ho-
mologous IBV Ark-DPI strain via the oculo-nasal route.
The challenge virus dose titer was 2 × 105.8 EID50 per
bird. Chicks were weighed weekly starting at 3 d of age
(0 dpv) and until 24 d of age (21 dpv).
Serum IgG Antibody
Blood was collected from all birds via wing vein punc-
ture at 7, 14, 21 dpv and 6 d post-infection (dpi). IBV-
specific IgG titers in the sera were assessed using a
commercial IBV enzyme-linked immunosorbent assay
(ELISA) (IDEXX, Westbrook, ME) according to the
manufacturer’s instructions. All samples were tested in
duplicate. Samples with titers higher than 396 were con-
sidered positive, according to the manufacturer specifi-
cations.
Tear IgA Antibody
Tears were collected from each chicken at 14 and
21 dpv and 6 dpi. Tears were diluted 1:5 in sample
diluent of ELISA kits and tested in duplicate. IBV
specific IgA was measured using a commercial IgG
ELISA kit (IDEXX) with substitution of the conju-
gated anti-chicken IgG antibody for a HRP conjugated
anti-chicken IgA antibody (Gallus Immunotech, Cary,
NC). The conjugated IgA antibody was used at a 1:1000
dilution. Results were reported as optical density (OD)
measured at 650 nm wavelength using a spectropho-
tometer (BioTek, Winoosk, VA).
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Flow Cytometry
At 11 dpv and 6 dpi, blood was collected in a hep-
arinized tube from 2 to 3 birds per group for isola-
tion of peripheral blood mononuclear cells (PBMC).
The same birds were euthanized and the spleen was
removed. A single cell suspension was obtained from
the spleens by mechanical disruption as described
(van Ginkel et al., 2008). Blood or spleen suspen-
sions were layered over a histopaque 1077 gradient
(Sigma-Aldrich, St. Louis, MO) at room tempera-
ture and centrifuged. The interface was removed and
washed. Live cells were counted by trypan blue exclu-
sion. Cells were adjusted to 1 × 106 per mL and stained
with mouse anti-chicken monocyte/macrophage-FITC,
CD4-PE, and CD8α-Alexa Fluor 647 conjugated an-
tibodies (Southern Biotech, Birmingham, AL) to de-
tect monocytes/macrophages, CD4 T cells and CD8α
T cells, respectively. After staining, cells were washed
and fixed in 4% paraformaldehyde. Immune cell popula-
tions were detected using a Becton Dickinson FACScan
(Franklin Lake, NJ).
Viral Load
IBV RNA was isolated from tears obtained 7 dpv
and 6 dpi using the QIAamp Viral RNA Mini Kit
in a QIAcube (Qiagen, Redwood, CA), following
the manufacturer’s instructions. Viral load was as-
sessed by RT-qPCR as described in (de Quadros,
2011), using the QuantiTect Multiplex PCR Master
Mix (Qiagen). In a 20 μL reaction, 5 μL of iso-
lated RNA was added to 15 μL of master mix (10
μL 2× buffer, 0.2 μL enzyme mix, 1 μL primer
mix, and 3.8 nuclease-free water). The primer mix
contained primers HmqF2 (ATACTCCTAACTAATG-
GTCAACAATG) and HmqR (GGCAAGTGGTCTG-
GTTCAC) at a concentration of 10 pmol/μL. These
primers amplify a 134 base-pair fragment of the
IBV M gene. In addition, we used the probe HmQs
(CAAGCCACTGACCCTCACAATAA) modified with
6–FAM and Black Hole Quencher at a concentration of
5 pmol/μL. The thermal profile consisted of an initial
denaturation step of 15 min at 95◦C and 45 cycles of
denaturation for 60 seconds at 94◦C, annealing for 30
seconds at 50◦C and extension for 30 seconds at 60◦C.
Fluorescent data were collected after annealing and re-
ported as Cq values.
Respiratory Sounds
Each chicken was evaluated for respiratory sounds
at 4, 5, and 6 dpi as we previously described (Toro
et al., 2012). In brief, severity scores were recorded as
(0) no signs, (1) mild nasal rales or upper respiratory
tract sounds, (2) moderate tracheal rales, or (3) severe
respiratory sounds audible from a 20-cm distance. An
index was calculated based on the severity of the signs.
Respiratory index = (
∑
respiratory scores per group /
number of birds per group × 3) ×100, where 3 is the
highest respiratory score.
Histopathology and Histomorphometry
At 6 dpi, birds were euthanized, tracheas were col-
lected, and slides were prepared and stained with
haematoxylin and eosin for histopathological analysis.
Tracheal histomorphometry was performed on trachea
sections at 40× magnification measuring mucosal thick-
ness using the NIH Image J software. In addition, tra-
cheal deciliation was assessed on a scale from 1 to 4
where 1 represented normal, 2 focal, 3 multifocal, and 4
diffuse cilia loss as described by Jackwood et al. (2015).
Statistical Analysis
Data was statistically analyzed using Prism Graph-
pad 5. Body weights were analyzed by two-way analysis
of variance (ANOVA) followed by Tukey test for group
comparisons. All other measurements were analyzed us-
ing Kruskal-Wallis test, followed by Dunn test for group
comparisons. Significance was determined at P < 0.05.
Flow cytometry data was analyzed using FlowJo soft-
ware (Ashland, OR).
RESULTS
Vaccine Virus Viability after Mixed with DE
Viral titers of the vaccine viruses with and without
the addition of 20 mg/mL DE were measured in order to
detect the effect of DE on virus viability. The titer of the
vaccine virus reconstituted in TPB was 105.38 EID50%
per milliliter compared to 105.77 EID50% per milliliter
for the virus reconstituted in TPB with DE under the
same conditions.
Chicken Body Weight and Mortality
No significant differences (P > 0.05) were detected in
live body weights between the different chicken groups
at 0, 7, and 14 dpv (data not shown). At 21 dpv,
the ocular and spray IBV groups showed lower body
weights compared with ocular and spray DE and DE-
IBV groups.
Two chickens, one from the ocular IBV+DE and the
second from the ocular IBV group, died due to causes
not related to the experiment.
Serum IgG Antibodies
All IBV-vaccinated groups (spray DE+IBV, spray
IBV, ocular DE+IBV, and ocular IBV) showed a slight
increase in IgG titers compared to Spray DE and oc-
ular DE groups at 7, 14, and 21 dpv (Table 2). Six d
after the challenge, both ocular DE+IBV and ocular
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Table 2. Serum IBV IgG titers measured by ELISA after IBV vaccination and challenge in
the different experimental groups. Data are shown as mean ± standard error.
Days post-vaccination Days post infection
Groups 7 14 21 6
Spray DE+IBV 38.5 ± 6.4a 28.6 ± 7.7ns 29.5 ± 8.7ns 78.7 ± 26.1a,b,c
Spray IBV 35.1 ± 8.2a 36.5 ± 26.5ns 35.7 ± 16.1ns 21.3 ± 7.1a,b,c
Spray DE 0 ± 0b 0 ± 0ns 6.6 ± 4.2ns 19.8 ± 11.5b,c
Ocular DE+IBV 18.1 ± 9.5a,b 44.2 ± 15.2ns 29 ± 9.9ns 317.6 ± 87.9a,b
Ocular IBV 46.6 ± 9.3a 28.2 ± 6.8ns 60.4 ± 33.7ns 357.9 ± 76.6a
Ocular DE 0 ± 0b 0 ± 0ns 8 ± 4.9ns 0 ± 0c
Lowercase superscripts indicate significant differences between groups (P < 0.05).
nsNot statistically significant.
Table 3. Tear IBV IgA optical density (OD) measured by ELISA after IBV vaccination and
challenge in the different experimental groups. Data are shown as net OD (net OD = OD
of sample – OD of blank). Tears were diluted 1:5 with sample diluent prior being assayed.
OD was measured at 650 nm. Data are shown as mean ± standard error.
Days post-vaccination Days post infection
Groups 14 21 6
Spray DE+IBV 0.0012 ± 0.0004b 0.0088 ± 0.004ns 0.0234 ± 0.0059ns
Spray IBV 0.0044 ± 0.0022a,b 0.0116 ± 0.0014ns 0.018 ± 0.0052ns
Spray DE 0.0024 ± 0.0013b 0.0096 ± 0.0024ns 0.037 ± 0.0105ns
Ocular DE+IBV 0.0474 ± 0.0149a,b 0.019 ± 0.0055ns 0.0523 ± 0.03ns
Ocular IBV 0.0396 ± 0.0127a 0.0322 ± 0.0209ns 0.0601 ± 0.0193ns
Ocular DE 0.003 ± 0.0007a,b 0.0092 ± 0.0004ns 0.0216 ± 0.0038ns
Lower case superscripts indicate significant differences between groups (P < 0.05).
nsNot statistically significant.
Table 4. Percentage of CD4+ T cells, CD8+ T cells, and monocytes/macrophages of the total isolated cells from chicken
blood and spleen at 11 dpv.
Blood1 Spleen
Groups % CD4+ T cells % CD8+ T cells % Monocytes % CD4+ T cells % CD8+ T cells % Macrophages
Spray DE+IBV 8.4 4.8 0.3 9.4 ± 1ns 7.7 ± 1ns 5 ± 1.6ns
Spray IBV 4.6 3.4 0.2 9.2 ± 0.7ns 4.9 ± 0.9ns 4.1 ± 0.4ns
Spray DE 5.6 3.7 0.2 11.5 ± 4.4ns 3.9 ± 1ns 5.8 ± 1.4ns
Ocular DE+IBV 3.6 2.1 0.2 8.7 ± 1.2ns 6.1 ± 1.6ns 4.5 ± 0.5ns
Ocular IBV 6.7 2.1 0.2 9.4 ± 2ns 8 ± 2.4ns 6.4 ± 0.5ns
Ocular DE 3.4 1.3 0.1 9.1 ± 1.1ns 6 ± 0.4ns 5.7 ± 1.6ns
1samples were pooled.
nsNot statistically significant.
Data are shown as mean ± standard error.
IBV groups showed higher IgG responses (P < 0.05)
than spray vaccinated and DE only groups (Table 2).
Tear IgA Antibodies
Similar to the serum IgG responses, the ocular
DE+IBV and ocular IBV only groups exhibited higher
tear IgA responses at all time points (Table 3). At 14
dpv, the ocular DE+IBV group showed the highest net
IgA response (OD: 0.047) followed by the ocular IBV
group (OD: 0.040). After the challenge, the intraocu-
larly vaccinated groups continued to show the highest
IgA values (0.052 and 0.060, respectively), even though
differences were not significant (Table 3).
Flow Cytometry
Flow cytometric analysis of PBMCs showed that
the spray DE+IBV group had the highest frequen-
cies of CD4+ and CD8+ T cells, as well as mono-
cytes at 11 dpv (Table 4). In contrast, ocular DE
vaccinated chickens had the lowest CD4+ and CD8+
T cells frequencies. There were no statistical dif-
ferences between the groups in the frequencies of
CD4+ T cells, CD8+ T cells and macrophages at 11
dpv in the spleen. The spray DE+IBV group had
higher percentages of cell populations (CD4+, CD8+
T cells and macrophages) than the spray IBV group,
while the opposite was observed between the groups
that had been intraocularly vaccinated with DE+IBV
or IBV only.
Table 5 illustrates the percentage of CD4+ T
cells, CD8+ T cells and monocytes/macrophages
in blood and spleen at 6 d following the chal-
lenge. There were no significant changes in the fre-
quency of cells in blood and splenic tissues between
groups.
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Table 5. Percentage of CD4+ T cells, CD8+ T cells, and monocytes/macrophages of the total isolated cells from chicken
blood and spleen at 6 dpi.
Blood Spleen
Groups % CD4+ T cells % CD8+ T cells % Monocytes % CD4+ T cells % CD8+ T cells % Macrophages
Spray DE+IBV 15.6 ± 6ns 3.4 ± 1ns 5.4 ± 1.7ns 16.1 ± 2.1ns 21.8 ± 4.6ns 3.3 ± 0.4ns
Spray IBV 12.2 ± 1.5ns 3.3 ± 0.6ns 3.7 ± 0.7ns 11.5 ± 1.5ns 13.1 ± 1.6ns 1.7 ± 0.5ns
Spray DE 8.8 ± 0.6ns 2 ± 0.4ns 3.2 ± 0.3ns 15.6 ± 2.2ns 17.3 ± 2.9ns 2.3 ± 0.6ns
Ocular DE+IBV 6.5 ± 1.4ns 1.8 ± 0.4ns 1.7 ± 0.2ns 18.2 ± 3.4ns 21 ± 5ns 3 ± 0.6ns
Ocular IBV 8.1 ± 1ns 2.9 ± 0.8ns 1.7 ± 0.3ns 9.3 ± 1.7ns 8.1 ± 1.9ns 2.5 ± 0.5ns
Ocular DE 8.9 ± 0.8ns 2.4 ± 0.1ns 2.7 ± 0.4ns 14 ± 2.9ns 12.5 ± 3.1ns 2.2 ± 0.2ns
Data are shown as mean ± standard error.
nsNot statistically significant.
(A) (B)
Figure 1. IBV viral load in tears detected by RT-qPCR. A: viral load at 7 dpv (10 d of age); B: viral load at 6 dpi (27 dpv, 30 d of age).
Error bars represent the standard error. Letters represent significant differences among groups.
IBV Viral Load
Seven d after the vaccination, the IBV viral load
in the DE+IBV and IBV ocular groups was higher
(P < 0.05) than in the spray IBV and DE-IBV vac-
cinated groups (Figure 1A). Six d after the challenge (6
dpi), the DE+IBV and IBV ocular vaccinated groups
displayed lower IBV loads in tears (P < 0.05) com-
pared to the spray IBV vaccinated and control groups
(Figure 1B). There were no significant viral load dif-
ferences between DE+IBV groups and IBV vaccinated
groups.
Respiratory Sounds
Spray DE and ocular DE groups showed the high-
est respiratory index on all d after the IBV challenge.
In contrast, the ocular IBV group had no respiratory
sounds at all times. Ocular DE+IBV showed the high-
est level of respiratory sounds of all the IBV vaccinated
groups with a reduction at 6 dpi (Figure 2). The spray
DE+IBV group had a higher respiratory index than the
spray IBV group at 4 dpi. Respiratory sounds decreased
at 5 dpi, disappearing at 6 dpi. Spray DE+IBV showed
decreased respiratory signs from 4 to 6 dpi, whereas
spray IBV group showed increasing signs.
Figure 2. Respiratory signs index at 4, 5, and 6 dpi. Low case letters
represent significant differences among groups. Respiratory index was
calculated using the formula R = (
∑
respiratory scores per group /
number of birds per group × 3) ×100.
Histopathology
Six d after the homologous IBV challenge, differences
among groups were not significant. The addition of DE
as adjuvant to the vaccine slightly increased mucosal
thickness and deciliation score in both spray and ocular
vaccinated groups (Table 6).
DISCUSSION
In this study, we formulated an experimental Ark-
DPI live vaccine using DE as an adjuvant to improve
the antigen delivery in the mucosa enhancing the mu-
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Table 6. Mean tracheal mucosal thickness and deciliation scores at 6 dpi in the different experimental groups.
Spray DE+IBV Spray IBV Spray DE Ocular DE+IBV Ocular IBV Ocular DE
Mucosal thickness1 751 ± 72ns 628 ± 93ns 718 ± 117ns 571 ± 79ns 541 ± 116ns 891 ± 83ns
Deciliation score2 3.8 ± 0.2ns 3.4 ± 0.4ns 4.0 ± 0.0ns 2.5 ± 0.3ns 2.0 ± 0.6ns 4.0 ± 0.0ns
1Mucosal thickness was measured using ImageJ at 40× magnification image.
2Deciliation score was assessed using a scale from 1 to 4 where 1 (normal), 2 (focal), 3 (multifocal), and 4 diffuse).
nsNot statistically significant.
Data are shown as mean ± standard error.
cosal immune responses against IBV. First, we tested
whether mixing DE with IBV live vaccine could af-
fect the viral viability. DE did not affect the overall
viral titer or the ability of the virus to replicate in em-
bryonated chicken eggs. Unpublished experiments per-
formed in our lab showed similar results when a lento-
genic NDV vaccine was blended into a DE solution.
These results demonstrate the innocuity of DE for these
2 live viruses.
During the in-vivo study, we tested whether DE had
any detrimental effect on live body weight following
vaccination. No effects on body weight between chicken
groups were detected at 7 and 14 d. Similar results were
obtained when we used DE as an adjuvant in an exper-
imental NDV inactivated vaccine (Nazmi et al., 2017).
We saw differences in body weight between the groups
at d 21; however, groups with heavier body weights con-
tained higher male-to-female ratio. Most likely these
differences in weight were not related to the vaccina-
tion treatment.
We characterized the effect of adding DE to the IBV
vaccine on different immunological parameters. The
IBV-IgG titers in serum of all birds after vaccination
were below the threshold specified in the commercial
ELISA. This result can be attributed to a low experi-
mental vaccine dose of 103.67 EID50%, however the RT-
qPCR results showed that birds took the vaccine. After
a homologous viral challenge, we saw a better response
in birds inoculated intraocularly than in spray vacci-
nated groups.
The ocular DE+IBV group showed the highest IBV-
specific IgA responses in tears at 14 dpv followed by the
ocular IBV group, while the spray-vaccinated groups
had lower titers (Table 3). While most of these results
showed to be non-statistically significant the Ocular
IBV IgA values showed to be statistically higher than
spray DE+IBV and Spray DE. After the viral chal-
lenge, no differences were detected between the groups.
The better efficacy of the ocular vaccination, compared
with the spray cabinet, was shown by the higher in-
crease of IgG and IgA titers in the groups vaccinated
by that route after the challenge. Other studies also
found that ocular vaccination of broiler chickens with
IBV Ark gave sufficient protection compared to vacci-
nation with a hatchery spray cabinet (Roh et al., 2013;
Roh et al., 2015).
The flow cytometric analysis did not show differences
in the frequencies of CD4+ T cells, CD8+ T cells and
monocytes/macrophages in blood and spleen at 11 dpv
and 6 dpi. Considering that the route of vaccination
and challenge was mucosal, it is possible that immune
cells were predominantly recruited at local mucosal sites
rather than at systemic organs. For instance, the fre-
quency of effector T cells was significantly increased in
Harderian glands at 11 dpv of an ocular IBV vaccine,
but not in spleen (Gurjar et al., 2013). Intra-tracheal
and intra-nasal infection with IBV recruited natural
killer cells to lung at 1 dpi and to blood at 1 and 4
dpi (Vervelde et al., 2013). Macrophages also increased
in trachea and lung at 1 dpi (Kameka et al., 2014). Col-
lectively, selection of different tissues and time points
might lead to a better understanding of the role of im-
mune cells in IBV protection.
In view of the poor antibody responses after vaccina-
tion and in order to confirm vaccine take, we tested IBV
viral load in tears by RT-qPCR at 7 dpv. We found that
both spray-vaccinated groups had a lower viral load at
7 dpv than the groups that had been vaccinated in-
traocularly. This correlates with results by others in
which they correlate higher vaccine load early after vac-
cination with adequate protection (Roh et al., 2013). A
goal of an ideal vaccine is to decrease viral shedding
after challenge. In this work we found that both ocular
groups had lower viral loads in tears at 6 dpi. As the
immunological results, this shows a better protection
when the vaccine is applied intraocularly.
In order to assess the protection conferred by our
experimental vaccines we assessed respiratory sounds
after challenge. Only the ocular IBV group did not
show respiratory signs confirming the effectiveness of
this vaccination route in protecting chickens but also
suggesting that the addition of DE to the live IBV Ark
vaccine does not confer better protection to the homol-
ogous challenge. An interesting trend was found in the
respiratory signs assessment; a decrease in respiratory
signs in the Spray DE+IBV group from d 4 to 6 post
infection. This trend correlates with increasing IgG an-
tibodies. Unfortunately, no statistical significance was
encountered.
The histopathology confirmed the respiratory sounds
assessment. The groups mock vaccinated with DE alone
either by spray cabinet or intraocularly showed higher
mucosal thickness and deciliation scores, indicating the
efficacy of the vaccination. The lack of significant dif-
ferences might be due to the reduced number of birds
per group.
In conclusion, there were few indications that adding
DE to Ark-DPI live vaccines had any advantages in the
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immune responses and protection against IBV homol-
ogous challenges under experimental conditions. Ark
vaccines administered by hatchery spray cabinet elicit
weaker immune responses and protection against an
IBV homologous challenge compared to the same vac-
cine delivered via the ocular route.
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